Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is experiencing significant growth, as evidenced by a nearly 30% sequential increase in product revenue in 4Q25, reaching approximately $87 million, largely driven by the demand for Amtagvi. The company has improved its gross margin from 35% to around 50% through tighter operational control, enhanced manufacturing success, and cost optimization, indicating stronger financial health and operational efficiencies. Additionally, the expansion of its ATC network is expected to enhance patient access and drive further growth, while ongoing improvements in manufacturing processes and tumor procurement practices bolster the prospects for successful commercialization of its therapies.

Iovance Biotherapeutics Inc. reported higher SG&A expenses of $36.4 million, exceeding expectations, which raises concerns about operational cost management amid the ongoing development phase of its T-cell therapies. Additionally, despite a reduction in Cost of Goods Sold (COGS) from 65% to 50%, the company faces substantial risks regarding regulatory approval and clinical efficacy, which could severely impact future revenue and growth prospects. Overall, the company is projected to underperform the sector over the next 12 months, with forecasts indicating a potential decline in share price due to both competitive and clinical risks related to its therapies.